Novavax Medical Information
DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Canada ONLY.
Information about the NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted) (also known as NVX-CoV2373)
NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older and as a homologous booster given approximately 6 months after completion of the second dose of the primary series in individuals 18 years of age and older.
Drug Identification Number (DIN): 02525364
Information on the NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted)
If your enquiry is regarding the NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted), you can find some useful information in the resources below.
Request Medical Information
Do you have a medical or scientific question about a Novavax medicinal product? Get in touch with Novavax Medical Information experts who will provide tailored, evidence-based, balanced, and up-to-date medical information.
Healthcare Professionals may request medical information via ONE of the following ways:
Option 1: Complete and submit a Medical Information Request Form by clicking on the button below.
Option 2: Call 1 855 239-9172 between 9 h 30 et 21 h 30 HT.
Report an Adverse Event (AE)
If you are concerned about an adverse event, it should be reported to the Health Canada at www.canada.ca.
Alternatively, adverse events of serious concern in association with a Novavax product can be reported at 1 855 239-9172 or https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html.